Levaquin against respiratory tract infections
Respiratory tract infections are the most common infectious diseases in humans. Despite the presence of a large number of antibiotics of different classes in medical practice, the results of treatment of these diseases do not improve, in fact over the last years there has been a clear trend to increased mortality from pneumonia in the developed world. The reason may be due, in particular, with increasing resistance of the main pathogens of community-acquired respiratory tract infections to many antibiotics. This explains the interest of clinicians for new antibacterial agents, which indicated a lower level of bacterial resistance.
Levofloxacin (Levaquin) is the most well studied drug among new fluoroquinolone and has the most extensive recorded testimony.
Levaquin is highly active against all of the natural pathogens of community-acquired pneumonia and its activity against gram-positive bacteria is 2-4 times higher than other fluoroquinolone – ciprofloxacin, ofloxacin and pefloxacin.
A large number of controlled clinical trials showed high efficacy of Levaquin in community-acquired respiratory infections (pneumonia, exacerbation of COPD, sinusitis) at a dose of 500mg once a day. The most important clinical data were obtained in these studies.
In 108 patients with severe pneumococcal pneumonia and bacteremia, the clinical efficacy of Levaquin in monotherapy was observed in 98 patients (90.7%), including 91.7% in patients with pneumonia caused by S. pneumoniae, resistant to penicillin or macrolide.
• Levaquin is as effective as b-lactam antibiotics in community-acquired respiratory infections – pneumonia, exacerbation of COPD, acute sinusitis.
• In monotherapy Levaquin is as effective as combined cycle (b-lactam + macrolide) with any degree of severity of pneumonia.
• Levaquin monotherapy has a higher efficiency compared with the combination of ceftriaxone / macrolide for severe community-acquired pneumonia requiring mechanical ventilation.
• Levaquin has advantage over macrolide antibiotics during exacerbation of COPD as the eradication of Haemophilus influenza, and the duration of DFS.
These advantages explain the fact that currently Levaquin takes the leading position in the structure of antibiotics in community-acquired pneumonia and exacerbation of COPD in the U.S. and Europe.
Levofloxacin (Levaquin) is the most well studied drug among new fluoroquinolone and has the most extensive recorded testimony.
Levaquin is highly active against all of the natural pathogens of community-acquired pneumonia and its activity against gram-positive bacteria is 2-4 times higher than other fluoroquinolone – ciprofloxacin, ofloxacin and pefloxacin.
A large number of controlled clinical trials showed high efficacy of Levaquin in community-acquired respiratory infections (pneumonia, exacerbation of COPD, sinusitis) at a dose of 500mg once a day. The most important clinical data were obtained in these studies.
In 108 patients with severe pneumococcal pneumonia and bacteremia, the clinical efficacy of Levaquin in monotherapy was observed in 98 patients (90.7%), including 91.7% in patients with pneumonia caused by S. pneumoniae, resistant to penicillin or macrolide.
• Levaquin is as effective as b-lactam antibiotics in community-acquired respiratory infections – pneumonia, exacerbation of COPD, acute sinusitis.
• In monotherapy Levaquin is as effective as combined cycle (b-lactam + macrolide) with any degree of severity of pneumonia.
• Levaquin monotherapy has a higher efficiency compared with the combination of ceftriaxone / macrolide for severe community-acquired pneumonia requiring mechanical ventilation.
• Levaquin has advantage over macrolide antibiotics during exacerbation of COPD as the eradication of Haemophilus influenza, and the duration of DFS.
These advantages explain the fact that currently Levaquin takes the leading position in the structure of antibiotics in community-acquired pneumonia and exacerbation of COPD in the U.S. and Europe.